Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott ACT I debut

This article was originally published in The Gray Sheet

Executive Summary

First patient is enrolled in firm's 50-site, 1,500 patient Asymptomatic Subjects with Significant Extracranial Carotid Occlusive Disease Trial (ACT I), Abbott announces March 31. The randomized clinical trial will compare carotid stenting to endarterectomy surgery in asymptomatic, surgery-eligible patients in support of a PMA for Mednova's self-expanding nitinol Xact carotid stent and Emboshield embolic protection device (1"The Gray Sheet" Jan. 24, 2005, p. 3)...

You may also be interested in...



Asymptomatic Carotid Stenting Evaluated By Abbott’s ACT-I Study

Abbott's ACT-I trial is the first randomized clinical trial comparing carotid stenting to endarterectomy surgery in asymptomatic, surgery-eligible patients

FDA Overhauls Its Purple Book

The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.

ICH Syncs Reproductive Toxicity Guidance With Current Science

The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.

UsernamePublicRestriction

Register

MT021853

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel